[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574898":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":43,"responsibleParty":61,"collaborators":26,"id":64,"slug":26,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"King Edward Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atorvastatin","ACTIVE_COMPARATOR","Atorvatstain 40mg OD",[13],"Drug: Atorvastatin 40 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Rosuvastatin","EXPERIMENTAL","Rosuvastatin 20mg",[19],"Drug: Rosuvastatin 20 mg\u002Fday",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rosuvastatin 20 mg\u002Fday","Rosuvastatin 20 mg \u002F Day for 24 weeks",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Atorvastatin 40 mg","Atorvastatin 40mg \u002F Day for 24 weeks",[9],[32,35],{"name":33,"affiliation":5,"role":34},"Uzma Malik","STUDY_CHAIR",{"name":36,"affiliation":5,"role":37},"Ali Hussnain","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","+923317641096","ahshah12@hotmail.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Lahore","Punjab Province","54000","Pakistan",{"type":51,"coordinates":52},"Point",[53,54],74.35071,31.558,{"lat":54,"lon":53},[57],{"name":58,"role":40,"phone":59,"phoneExt":26,"email":60},"AP Endocrinology","+923004683473","sidrah.lodhi@gmail.com",{"type":37,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Sidrah Lodhi","Assistant Professor of Endocrinology","100574898",false,"NCT06765265","Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\nAcute Coronary Syndrome\n\n25 OH-Vitamin D levels between 30-70ng\u002Fml\n\nExclusion Criteria:\n\nHypercalcemia\n\nhypocalcemia\n\npregnancy\n\nlactation\n\nhypersensitivity to statins\n\nhypothyroidism\n\nDeranged LFTs \\& RFTs\n\nUse of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)","ALL","18 Years","65 Years",{"count":73,"type":74},152,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months",[80],"Acute Coronary Syndromes",[82,83,84,85,86],"atorvastatin","rosuvastatin","Vitamin D","Triglyceride","Lipid Profile","2025-03-07",{"date":89,"type":90},"2025-03-11","ACTUAL",{"date":92,"type":90},"2025-01-05",{"date":94,"type":74},"2026-01-01",{"name":5,"class":6},1]